Addition of Bortezomib to Thalidomide-Dexamethasone as Post-ASCT Consolidation Therapy Significantly Increases Response and PFS in Multiple Myeloma

Patients with multiple myeloma (MM) had significantly increased rates of complete response (CR) and progression-free survival (PFS)—including superior PFS across poor prognosis subgroups—when postautologous stem cell transplantation (ASCT) consolidation therapy utilized bortezomib-thalidomide-dexamethasone compared with thalidomide-dexamethasone, investigators reported during the 53rd American Society of Hematology Annual Meeting and Exposition.

Sign In to MPR

Sign in with your MPR account

Keep me signed in Forgot your password?

Don't have one of these accounts?

Create an account for free »

Register for free with MPR

REGISTER FOR FREE WITH A MPR ACCOUNT

Registration acknowledges the Terms and Conditions and Privacy Policy

Already have an account?

Log in now »

FORGET YOUR PASSWORD?

Enter your MPR registration email address to receive a new password.

NEW PASSWORD SENT

Already have an account?

Log in now »

ALMOST DONE

Almost Done

Please confirm the information BELOW before Signing In

By registering you agree with our Terms and Conditions and Privacy Policy.

« CANCEL AND GO BACK

Thank you for registering with MPRxOnline.

Please take a moment to tell us a little more about yourself, so we can bring you specialized clinical content that’s most valuable to you.

NEED HELP? Contact Customer Service »